Advertisement
Australia markets closed
  • ALL ORDS

    8,013.80
    +11.00 (+0.14%)
     
  • ASX 200

    7,767.50
    +7.90 (+0.10%)
     
  • AUD/USD

    0.6660
    +0.0009 (+0.13%)
     
  • OIL

    82.39
    +0.65 (+0.80%)
     
  • GOLD

    2,345.90
    +9.30 (+0.40%)
     
  • Bitcoin AUD

    92,324.06
    +398.19 (+0.43%)
     
  • CMC Crypto 200

    1,280.55
    -3.28 (-0.26%)
     
  • AUD/EUR

    0.6218
    +0.0012 (+0.19%)
     
  • AUD/NZD

    1.0945
    +0.0018 (+0.16%)
     
  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     
  • NASDAQ

    19,789.03
    +37.98 (+0.19%)
     
  • FTSE

    8,221.65
    +41.97 (+0.51%)
     
  • Dow Jones

    39,164.06
    +36.26 (+0.09%)
     
  • DAX

    18,313.81
    +103.26 (+0.57%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

ResMed Stock Dives. Blame Eli Lilly’s Zepbound Trials for Sleep Apnea.

Strong results from Eli Lilly’s obesity medicine in a sleep apnea trial could upset the sleep apnea industry, while greatly expanding insurance coverage for the Lilly drug. Shares of ResMed which sells CPAP machines that treat sleep apnea, were falling sharply Monday. ResMed’s stock was down 11% to $183.34 near midday, putting it on track for its largest decline since Aug. 4, when it dropped 19%, according to Dow Jones Market Data.